Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.13
Peer-review started: July 29, 2020
First decision: October 18, 2020
Revised: November 5, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: January 24, 2021
Processing time: 171 Days and 16.9 Hours
Circulating tumor cells (CTCs) are the most applicable strategy in preventive oncology. The most puzzling items include the lack of: (1) The basic information on the migrated cells into the tumor and into the blood stream; (2) The categorized data for the personalized strategy of CTCs; (3) Information on the application of CTCs for the patients affected with brain tumors as early as possible; and (4) The data on the early detection of the brain tumors in the probands affected with brain tumor and the relatives through their pedigree. Hence, it was aimed to explore the developmental picture of CTC behavior in tumor (T) and blood in the brain neoplasms.
The key target to explore CTCs was revealed to be early detection; therefore, availability of adequate data on the pedigree of proband affected either with brain tumor or any other neoplastic disorder (s) will facilitate application of the preventive strategy for the probands’ relatives who are at risk of being affected with the neoplastic disorders.
In the cancer-prone families: The target objectives, include: (1) The family history of any neoplastic disorders in the proband’s pedigree and age of the onset for the target individuals; (2) The key information for each individual affected with neoplastic disorder including cancer; (3) Tracing and selecting the target relatives of the probands; and (4) Performing the CTC test for the selected individuals.
In the family of the probands without any history of the neoplastic disorders: In case of the influential micro-and/or macro-environmental hazards, the target offspring of the proband through the further generations may be selected for the performance of CTCs.
The novelty of this research is relied on the simple Manuel analysis, which provides an adequate single cell screening process. Based on this strategy, diverse pattern of intensity and categorization of different target proteins will be facilitated.
The course of evolution and possibility of metastatic event rely on the higher protein expression in CTCs. Such a finding is indicative of prognostic value. Besides, diversity in protein expression of the migrated cells into the both tumor and blood stream and diverse pattern of protein expression in both tissues are indicative of the occurrence of evolution. Besides, the harmonic co-expression between C-C chemokine ligand 2/epidermal growth factor and C-C chemokine ligand 2/vascular endothelial growth factor can facilitate the tumor progression including the metastatic event.
There is a diverse pattern of protein expression of the migrated cells at different territories including tumor and the bloodstream by performing CTCs by Manuel analytical strategy to unmask heterogeneity of the protein expression.
The direction of further research includes providing: (1) The educational/informative packages on the early detection by CTCs to the cancer clinics or the related hospitals with the available preventive cancer section; and (2) Cancer Genetic counselling to the referral cancer patients for performing an early detection of probable metastasis by CTCs test.